2013 年
1. Yoon JH, Jung SM, Park SH, Kato M, Yamashita T, Lee IK, Sudo K, Nakae S, Han JS, Kim OH, OhBC, Sumida T, Kuroda M, Ju JH, Jung KC, Park SH, Kim DK, Mamura M.:
Activin receptor-like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation ofSmad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes.
EMBO Mol Med 5(11):1720-1739,2013
2. Kawasaki A, Inoue N, Ajimi C, Sada KE, Kobayashi S, Yamada H, Furukawa H, Sumida T, Tohma S,Miyasaka N, Matsuo S, Ozaki S, Hashimoto H, Makino H, Harigai M, Tsuchiya N.:
Association of IRF5 polymorphism with MPO-ANCA-positive vasculitis in a Japanese population.
Genes Immun 14(8):527-529,2013
3. Furukawa H, Kawasaki A, Oka S, Shimada K, Matsui T, Ikenaka T, Hashimoto A, Okazaki Y,Takaoka H, Futami H, Komiya A, Kondo Y, Ito S, Hayashi T, Matsumoto I, Kusaoi M, Takasaki Y,Nagai T, Hirohata S, Setoguchi K, Suda A, Nagaoka S, Kono H, Okamoto A, Chiba N, Suematsu E,Fukui N, Hashimoto H, Sumida T, Ono M, Tsuchiya N, Tohma S.:
Association of a single nucleotide polymorphism in the SH2D1A intronic region with systemic lupus
erythematosus.
Lupus 22(5):497-503,2013
4. Umeda N, Matsumoto I, Ito I, Kawasaki A, Tanaka Y, Inoue A, Tsuboi H, Suzuki T, Hayashi T, Ito S,Tsuchiya N, Sumida T.:
Anti-citrullinated glucose-6-phosphate isomerase peptide antibodies in patients with rheumatoid
arthritis are associated with HLA-DRB1 shared epitope alleles and disease activity.
Clin Exp Immunol 172(1):44-53,2013
5. Shimane K, Kochi Y, Suzuki A, Okada Y, Ishii T, Horita T, Saito K, Okamoto A, Nishimoto N,Myouzen K, Kubo M, Hirakata M, Sumida T, Takasaki Y, Yamada R, Nakamura Y, Kamatani N,Yamamoto K.:
An association analysis of HLA-DRB1 with systemic lupus erythematosus and rheumatoid arthritis ina Japanese population: effects of *09:01 allele on disease phenotypes.
Rheumatology 52(7):1172-1182,2013
6. Hasegawa M, Asano Y, Endo H, Fujimoto M, Goto D, Ihn H, Inoue K, Ishikawa O, Kawaguchi Y,Kuwana M, Ogawa F, Takahashi H, Tanaka S, Sato S, Takehara K.:
Serum chemokine levels as prognostic markers in patients with early systemic sclerosis: a multicenter,prospective, observational study.
Mod Rheumatol 23(6):1076-1084,2013
7. Sumida T, Tsuboi H, Iizuka M, Asashima H, Matsumoto I.:
Anti-M3 muscarinic acetylcholine receptor antibodies in patients with Sjögren's syndrome.
Mod Rheumatol 23(5): 841-845,2013
8. Iizuka M, Tsuboi H, Matsuo N, Kondo Y, Asashima H, Matsui M, Matsumoto I, Sumida T.:
The crucial roles of IFN-γ in the development of M3 muscarinic acetylcholine receptor induced
Sjögren's syndrome-like sialadenitis.
Mod Rheumatol 23(3):614-616, 2013
9. Suzuki T, Horikoshi M, Sugihara M, Hirota T, Ogishima H, Umeda N, Kondo Y, Tsuboi H, Hayashi
T, Chino Y, Matsumoto I, Sumida T.:
T herapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumornecrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI.
Mod Rheumatol 23(4):782-787,201310. Ishiguro N, Yamamoto K, Katayama K, Kondo M, Sumida T, Mimori T, Soen S, Nagai K, Yamaguchi
T, Hara M; Iguratimod-Clinical Study Group.:
Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses ofmethotrexate: a randomized, double-blind, placebo-controlled trial.
Mod Rhumatol 23(3):430-439,2013
11. Anami A, Fukushima K, Takasaki Y, Sumida T, Waguri M, Wake N, Murashima A.:
The predictive value of anti-SS-A antibodies titration in pregnant women with fetal congenital heartblock.
Mod Rhumatol 23(3):653-658,2013
12. Tsuboi H, Hagiwara S, Asashima H, Umehara H, Kawakami A, Nakamura H, Sano H, Tsubota K,Ogawa Y, Takamura E, Saito I, Inoue H, Nakamura S, Moriyama M, Takeuchi T, Tanaka Y, Hirata S,Mimori T, Matsumoto I, Sumida T.:
Validation of different sets of criteria for the diagnosis of Sjögren's syndrome in Japanese patients.
Mod Rheumatol 23(2):219-225, 2013